Poly(ADP-ribose) polymerase inhibition and its potential use in malignant melanoma

References

• Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol.19, 2370–2380 (2001).
   PubMed Web of Science ®Google Scholar
• Eggermont AM. Current status of interferon-α in the treatment of melanoma. Cancer Chemother. Biol. Response Modif.22, 729–737 (2005).
   PubMedGoogle Scholar
• Hancock B, Wheatley K, Ives N, Gore M. Adjuvant interferon therapy for melanoma. J. Clin. Oncol.23, 2431 (2005).
   PubMedGoogle Scholar
• Huncharek M, Caubet JF, McGarry R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res.11, 75–81 (2001).
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol.4, 748–759 (2003).
   PubMed Web of Science ®Google Scholar
• Ames BN, Gold LS. Endogenous mutagens and the causes of aging and cancer. Mutat. Res.250, 3–16 (1991).
   PubMed Web of Science ®Google Scholar
• Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat. Res.511, 145–178 (2002).
   PubMed Web of Science ®Google Scholar
• Hansen K, Kelly M. Review of mammalian DNA repair and translational implications. J. Pharmacol. Exp. Ther.295, 1–9 (2000).
   PubMed Web of Science ®Google Scholar
• Hoeijmakers JH. Genone maintenance mechanisms for preventing cancer. Nature411, 360–374 (2001).
   Google Scholar
• Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat. Med.10, 789–799 (2004).
   PubMed Web of Science ®Google Scholar
• Fink D, Aebi S, Howell S. The role of DNA mismatch repair in drug resistance. Clin. Cancer Res.4, 1–6 (1998).
   PubMed Web of Science ®Google Scholar
• Soejima H, Zhao W, Mukai T. Epigenetic silencing of the MGMT gene in cancer. Biochem. Cell Biol.83, 429–437 (2005).
   PubMedGoogle Scholar
• Park Y, Gerson SL. DNA repair defects in stem cell function and aging. Annu. Rev. Med.56, 495–508 (2005).
   PubMed Web of Science ®Google Scholar
• Margison G, Koref MS, Povey A. Mechanisms of carcinogenicity/chemotherapy by O6-methylguanine. Mutagenesis17, 483–487 (2002).
   PubMed Web of Science ®Google Scholar
• Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev.31, 603–617 (2005).
   PubMed Web of Science ®Google Scholar
• Bradbury PA, Middleton MR. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs15, 421–426 (2004).
   PubMed Web of Science ®Google Scholar
• Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev.23, 35–61 (1997).
   PubMed Web of Science ®Google Scholar
• Bleehen NM, Newlands ES, Lee SM et al. Cancer research campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol.13, 910–913 (1995).
   PubMed Web of Science ®Google Scholar
• Brada M, Hoang-Xuang K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol.12, 259–266 (2001).
   PubMed Web of Science ®Google Scholar
• Yung WKA, Albright RE, Olson J et al. Multicentre Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol.17, 2762–2771 (1999).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Grob JJ, Aaronson N et al. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol.18, 158–166 (2000).
   PubMed Web of Science ®Google Scholar
• Tentori L, Graziani G, Gilberti S et al. Triazene compounds increase apotosis in O6-alkylguanine-DNA alkytransferase deficient leukaemic cell lines. Leukemia9, 1888–1895 (1995).
   PubMed Web of Science ®Google Scholar
• Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signalling induction of apotosis by alkylating agents. Proc. Natl Acad. Sci. USA96, 10764–10769 (1999).
   PubMed Web of Science ®Google Scholar
• Karran P, Hampson R. Genomic instability and tolerance to alkylating agents. Cancer Surv.28, 69–85 (1996).
   PubMedGoogle Scholar
• D'Atri S, Tentori L, Lacal PM et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol.54, 334–341 (1998).
   PubMed Web of Science ®Google Scholar
• Belanich M, Pastor M, Randall T et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res.56, 783–788 (1996).
   PubMed Web of Science ®Google Scholar
• Friedman HS, McLendon RE, Kerby T et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J. Clin. Oncol.16, 3851–3857 (1998).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Lunn JM, Morris C et al. O6-methylguanine-DNA methyltransferase in pretreatment tumor biopsies as a predictor of response to temozolomide in melanoma. Br. J. Cancer78, 1199–1202 (1998).
   PubMed Web of Science ®Google Scholar
• Lee SM, Thatcher N, Crowther D, Margison GP. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br. J. Cancer69, 452–456 (1994).
   PubMed Web of Science ®Google Scholar
• Middleton MR, Lorigan P, Owen J et al. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a Phase II study. Int. J. Cancer88, 469–473 (2000).
   PubMed Web of Science ®Google Scholar
• Chambon P, Weil J, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid sythesizing nuclear enzyme. Biochem. Biophys. Res. Commun.11, 39 (1963).
   PubMed Web of Science ®Google Scholar
• de Murcia G, Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci.19, 172–176 (1994).
   PubMed Web of Science ®Google Scholar
• Davidovic L, Vodenicharov M, Affar EB, Poirier GG. Importance of poly (ADP-ribose) glycohydrolase in the control of poly (ADP-ribose) metabolism. Exp. Cell Res.268, 7–13 (2001).
   PubMed Web of Science ®Google Scholar
• Satoh MS, Lindahl T. Role of poly (ADP-ribose) formation in DNA repair. Nature356, 356–358 (1992).
   PubMed Web of Science ®Google Scholar
• Durkacz B, Omidiji O, Gray D, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature283, 593–596 (1980).
   PubMed Web of Science ®Google Scholar
• Boulton S, Pemberton LC, Porteous JK et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer72, 849–856 (1995).
   PubMed Web of Science ®Google Scholar
• Calabrese CR, Almassy R, Barton S et al. Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl Cancer Inst.96, 56–67 (2004).
   PubMed Web of Science ®Google Scholar
• Cheng CL, Johnson SP, Keir ST et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol. Cancer Ther.4, 1364–1368 (2005).
   PubMed Web of Science ®Google Scholar
• Curtin NJ, Wang LZ, Yiakouvaki A et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin. Cancer Res.10, 881–889 (2004).
   PubMed Web of Science ®Google Scholar
• Miknyoczki SJ, Jones-Bolin S, Pritchard S et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther.2, 371–382 (2003).
   PubMed Web of Science ®Google Scholar
• Tentori L, Leonetti C, Scarsella M et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood99, 2241–2244 (2002).
   PubMed Web of Science ®Google Scholar
• Tentori L, Leonetti C, Scarsella M et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res.9, 5370–5379 (2003).
   PubMed Web of Science ®Google Scholar
• Masutani M, Nozaki T, Nakmoto K et al. The response of Parp knockout mice against DNA damaging agents. Mutat. Res.462, 159–166 (2000).
   PubMed Web of Science ®Google Scholar
• Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res.460, 1–15 (2000).
   PubMed Web of Science ®Google Scholar
• de Murcia JM, Niedergang C, Trucco C et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl Acad. Sci. USA94, 7303–7307 (1997).
   PubMed Web of Science ®Google Scholar
• Curtin N. PARP inhibitors for cancer therapy. Expert Rev. Mol. Med.7, 1–20 (2005).
   PubMedGoogle Scholar
• Masutani M, Nakagama H, Sugimura T. Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease. Cell Mol. Life Sci.62, 769–783 (2005).
   PubMed Web of Science ®Google Scholar
• Purnell MR, Whish WJD. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J.185, 775–777 (1980).
   PubMed Web of Science ®Google Scholar
• Griffin RJ, Pemberton LC, Rhodes D et al. Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anticancer Drug Des.10, 507–514 (1995).
   PubMedGoogle Scholar
• Southan G, Szabo C. Poly(ADP-ribose) ploymerase inhibitors. Curr. Med. Chem.10, 321–340 (2003).
   PubMed Web of Science ®Google Scholar
• Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br. J. Cancer78, 1269–1277 (1998).
   PubMed Web of Science ®Google Scholar
• Delaney CA, Wang LZ, Kyle S et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res.6, 2860–2867 (2000).
   PubMed Web of Science ®Google Scholar
• Plummer ER, Middleton MR, Jones C et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin. Cancer Res.11, 3402–3409 (2005).
   PubMed Web of Science ®Google Scholar
• Plummer ER, Middleton M, Wilson R et al. First in human Phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. J. Clin. Oncol.23(16), 208S–208S (2005).
   Google Scholar
• Staibano S, Pepe S, Lo Muzio L et al. Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region. Hum. Pathol.36, 724–731 (2005).
   PubMed Web of Science ®Google Scholar
• Shiobara M, Miyazaki M, Ito H et al. Hepatocellular carcinoma: treatment and recurrence marker. J. Gastroenterol. Hepatol.16, 338–344 (2001).
   PubMed Web of Science ®Google Scholar
• Hirai K, Ueda JC, Hayaishi O. Aberration of poly(adenosine diphosphate-ribose) metabolism in human cancer adenomatour polyps and cancers. Cancer Res.43, 3441–3446 (1983).
   PubMed Web of Science ®Google Scholar
• Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Res.45, 73–85 (2002).
   PubMed Web of Science ®Google Scholar
• Fiorillo C, Ponziani V, Giannini L et al. Beneficial effects of poly (ADP-ribose) polymerase inhibition against the reperfusion injury in heart transplantation. Free Radic. Res.37, 331–339 (2003).
   PubMed Web of Science ®Google Scholar
• Szabo C. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions. Curr. Vasc. Pharmacol.3, 301–303 (2005).
   PubMedGoogle Scholar
• Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumors with inhibitors of poly(ADP-ribose) polymerase. Nature434, 913–917 (2005).
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434, 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• McCabe N, Lord CJ, Tutt AN et al. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly(ADP-ribose) polymerase: an issue of potency. Cancer Biol. Ther.4, 934–936 (2005).
   PubMed Web of Science ®Google Scholar
• Gallmeier E, Kern SE. Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition. Cancer Biol. Ther.4, 703–706 (2005).
   PubMed Web of Science ®Google Scholar